Scholar Rock Holding Corp (SRRK)
12.02
-0.50
(-3.99%)
USD |
NASDAQ |
May 21, 13:40
Scholar Rock Enterprise Value: 810.18M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 810.18M |
| May 17, 2024 | 807.79M |
| May 16, 2024 | 953.74M |
| May 15, 2024 | 931.41M |
| May 14, 2024 | 929.02M |
| May 13, 2024 | 899.51M |
| May 10, 2024 | 876.38M |
| May 09, 2024 | 972.09M |
| May 08, 2024 | 968.10M |
| May 07, 2024 | 983.25M |
| May 06, 2024 | 1.013B |
| May 03, 2024 | 1.036B |
| May 02, 2024 | 1.016B |
| May 01, 2024 | 1.005B |
| April 30, 2024 | 981.66M |
| April 29, 2024 | 999.20M |
| April 26, 2024 | 970.35M |
| April 25, 2024 | 924.90M |
| April 24, 2024 | 935.27M |
| April 23, 2024 | 991.09M |
| April 22, 2024 | 928.09M |
| April 19, 2024 | 916.13M |
| April 18, 2024 | 924.10M |
| April 17, 2024 | 904.17M |
| April 16, 2024 | 928.09M |
| Date | Value |
|---|---|
| April 15, 2024 | 874.66M |
| April 12, 2024 | 884.23M |
| April 11, 2024 | 941.65M |
| April 10, 2024 | 929.68M |
| April 09, 2024 | 993.48M |
| April 08, 2024 | 967.96M |
| April 05, 2024 | 959.19M |
| April 04, 2024 | 959.99M |
| April 03, 2024 | 1.026B |
| April 02, 2024 | 1.065B |
| April 01, 2024 | 1.151B |
| March 28, 2024 | 1.153B |
| March 27, 2024 | 973.11M |
| March 26, 2024 | 938.07M |
| March 25, 2024 | 1.017B |
| March 22, 2024 | 1.046B |
| March 21, 2024 | 1.109B |
| March 20, 2024 | 1.051B |
| March 19, 2024 | 949.75M |
| March 18, 2024 | 797.92M |
| March 15, 2024 | 895.25M |
| March 14, 2024 | 920.94M |
| March 13, 2024 | 1.015B |
| March 12, 2024 | 1.032B |
| March 11, 2024 | 1.007B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-45.07M
Minimum
Jul 01 2022
2.014B
Maximum
Mar 15 2021
497.74M
Average
304.43M
Median
Enterprise Value Benchmarks
| Amgen Inc | 223.04B |
| Eli Lilly and Co | 768.05B |
| Ocular Therapeutix Inc | 557.82M |
| Alpine Immune Sciences Inc | 4.151B |
| X4 Pharmaceuticals Inc | 125.13M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.85M |
| Total Expenses (Quarterly) | 58.42M |
| EPS Diluted (Quarterly) | -0.59 |
| Earnings Yield | -17.39% |
| Normalized Earnings Yield | -25.29 |